98%
921
2 minutes
20
Introduction: Diabetes mellitus has become a significant public health issue in India, with a considerable proportion of the population living with the condition. Type 2 Diabetes Mellitus (T2DM), commonly linked with obesity, is associated with metabolic abnormalities and vascular complications. Effective long-term glycemic control is important in preventing complications and improving patient outcomes.
Objective: To examine associations between demographic, anthropometric, clinical, and therapeutic characteristics and long-term glycemic control status in individuals with T2DM in 314 participants. Methodology and results: This is a longitudinal study conducted to evaluate factors such as demographic characteristics, clinical parameters, duration of T2DM, medication use, and comorbidities. Findings highlight the impact of age, gender, obesity, medication adherence, and comorbid conditions on glycemic control.
Conclusion: A multi-faceted approach, including lifestyle modifications, personalized treatment plans, and patient education, is essential for achieving optimal glycemic outcomes in T2DM management. .
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12122831 | PMC |
http://dx.doi.org/10.7759/cureus.83221 | DOI Listing |
Diabetes Metab Syndr Obes
September 2025
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Insulin therapy remains a cornerstone in the management of type 2 diabetes mellitus (T2DM), especially in patients experiencing progressive loss of pancreatic beta-cell function or those with inadequate glycemic control despite oral antidiabetic therapy. This review synthesized clinical outcomes from 44 peer-reviewed case reports published between 2019 and 2024, identified through systematic searches in PubMed and Scopus. The included cases involved 15 males and 29 females, with patient ages ranging from 11 to 91 years (mean 53 ± 20.
View Article and Find Full Text PDFJ Multidiscip Healthc
September 2025
School Public Health and Social Work, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia.
Background: Diabetes mellitus is a major health challenge among older adults in Asia. Challenges include limited healthcare access and poor self-care adherence. Continuity of care has emerged as a key strategy to enhance diabetes self-management in this population.
View Article and Find Full Text PDFDiabetes Obes Metab
September 2025
Department of Endocrinology, Peking University People's Hospital, Beijing, People's Republic of China.
Aim: To evaluate the long-term efficacy and safety data at 104 weeks in tirzepatide-treated participants with type 2 diabetes who had inadequate glycaemic control on metformin and/or sulfonylurea.
Materials And Methods: This post-hoc analysis was based on the SURPASS-4 data (NCT03730662), a multicenter, Phase III trial. Participants were randomised to receive tirzepatide (5, 10, or 15 mg) or insulin glargine.
Diabetes Metab Syndr Obes
September 2025
Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, People's Republic of China.
Aim: This 10-year study aimed to evaluate how glycaemic control, diabetes duration and coronary stenosis severity affect mortality in patients with stable coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) and to perform multifactorial risk analysis to find key modifiable factors for better risk stratification and secondary prevention.
Methods: This retrospective cohort study involved 150 patients with T2DM with chronic coronary syndrome who had coronary angiography at a single centre between 2011 and 2012. Demographic and biochemical data were collected.
Diabetes Obes Metab
September 2025
Department of Infectious Diseases, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
Aim: This meta-analysis aimed to evaluate the efficacy and safety of survodutide on glycemic control and weight loss in adults.
Methods: We systematically searched PubMed, Embase, the Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov for randomized controlled trials (RCTs) evaluating the efficacy and safety of survodutide up to 12 July 2025.